In cases where it is difficult to demonstrate the improvement of a drug or a device in hard endpoints such as mortality, we should look for softer and easier to prove endpoints. The problem is that these soft endpoints are often subjective (such as sensation of shortness of breath or angina pectoris) and they could<a href="https://solaci.org/en/2019/12/08/percutaneous-annuloplasty-in-functional-mitral-regurgitation-vs-sham-procedure/" title="Read more" >...</a>
AHA 2019 | TWILIGHT: Discontinue Aspirin after Acute Coronary Syndrome
This study findings confirm less bleeding at no extra cost of thrombotic events when aspirin is discontinued after an acute coronary syndrome (ACS). In the same line as the original TWILIGHT, this study focused on ACS patients alone (excluding STEMI) and confirmed that aspirin discontinuation after 3-month DAPT to continue with ticagrelor alone, reduced the<a href="https://solaci.org/en/2019/11/20/aha-2019-twilight-discontinue-aspirin-after-acute-coronary-syndrome/" title="Read more" >...</a>
Europe Grants Approval to Balloon-Expandable Valve in Low-Risk Patients; Self-Expanding Valve Still Waiting for It
The balloon-expandable valve has been granted approval in Europe for treatment of the complete risk spectrum of symptomatic severe aortic stenosis. Europe has recently approved an expanded indication for the Sapien 3 system for use in low-risk patients, as reported by Edward Lifesciences. Sapien 3, which includes the next-generation Sapien 3 Ultra, is the first transcatheter heart valve<a href="https://solaci.org/en/2019/11/15/europe-grants-approval-to-balloon-expandable-valve-in-low-risk-patients-self-expanding-valve-still-waiting-for-it/" title="Read more" >...</a>
Regional Course of Interventionism for the Clinical Cardiologist | with SOLACI’s Support
On November 30, 2019, the “I Regional Course of Interventionism for the Clinical Cardiologist” will take place in Chiclayo, Peru. The event will be held in the Muchick Room at Costa del Sol Hotel, organized by the Peruvian Society of Hemodynamics and Endovascular Interventionism (SOPHIE) with the support of SOLACI. The activity will be oriented to<a href="https://solaci.org/en/2019/11/13/regional-course-of-interventionism-for-the-clinical-cardiologist-with-solacis-support/" title="Read more" >...</a>
See the 2019 Bolivia Sessions presentations
The XXXVIII Regional SOLACI Sessions in Bolivia were an extremely successful scientific event. Renowned specialists in hemodynamics from all over Latin America presented their works and shared their knowledge in an event characterized by the utmost respect and comradeship. That is the reason why we share below those presentations, thanking these professionals for their contribution to<a href="https://solaci.org/en/2019/11/13/see-the-2019-bolivia-sessions-presentations/" title="Read more" >...</a>
Negative Impact of Pulmonary Hypertension in TAVR
Courtesy of Dr. Carlos Fava. The presence of pulmonary hypertension (PH) is frequent in severe aortic stenosis. This can be classified in: isolated pre-capillary PH, isolated post-capillary PH, and combined post-capillary and pre-capillary PH. At present, little research has looked into the disease from this perspective. The study looked at 1400 patients and divided them<a href="https://solaci.org/en/2019/11/13/negative-impact-of-pulmonary-hypertension-in-tavr/" title="Read more" >...</a>
SOLACI Symposium at SOCHICAR 2019
The Latin American Society of Interventional Cardiology is proud to present together with the Chilean Society of Cardiology (SOCHICAR) a joint symposium to take place during SOCHICAR 2019 on November 28 thru 30 at the Hotel del Mar in Viña del Mar (Chile). The session will be entirely dedicated to the analysis of “Controversies in the Management of<a href="https://solaci.org/en/2019/10/18/solaci-symposium-at-sochicar-2019/" title="Read more" >...</a>
TCT 2019 | SCOPE I: Self-Expanding Valve Acurate Neo Head to Head with Sapien 3
Courtesy of SBHCI. This work, which was presented during the TCT 2019 Scientific Sessions and simultaneously published in the Lancet, randomized patients to the ACURATE Neo prosthesis (n = 373) vs. the SAPIEN 3 (n = 367) in a head-to-head comparison involving 20 European sites. Transfemoral access was used in all patients. The study had a noninferiority design, and its primary<a href="https://solaci.org/en/2019/09/30/tct-2019-scope-i-self-expanding-valve-acurate-neo-head-to-head-with-sapien-3/" title="Read more" >...</a>
Should We Start Using the Retrograte Access in Critical Limb Ischemia?
Courtesy of Dr. Carlos Fava. Peripheral vascular disease in lower limbs is on the rise. Antegrade recanalization is associated with amputation and death, and therefore contraindicated. For a while we have been using the retrograde access when classic revascularization is not possible. Even though there is evidence in favor of this access, it is just<a href="https://solaci.org/en/2019/09/11/should-we-start-using-the-retrograte-access-in-critical-limb-ischemia/" title="Read more" >...</a>
The Real Impact of Peripheral Artery Disease in TAVR
Courtesy of Dr. Carlos Fava. The real incidence of peripheral artery (PAD) disease in TAVR remains unclear. Different reports still estimate it is between 10 and 46%, but they have shown it has a negative impact in evolution. 51,685 TAVR patients were analyzed. 12,740 of these patients presented PAD (24.6%). PAD patients tended to be<a href="https://solaci.org/en/2019/09/11/the-real-impact-of-peripheral-artery-disease-in-tavr/" title="Read more" >...</a>